کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5831906 | 1559759 | 2016 | 7 صفحه PDF | دانلود رایگان |

- Intranasal curcumin is effective in suppressing airway inflammation and airway Hyperresponsiveness (AHR).
- AHR has been attenuated by phospholipase A2 (sPLA2) activity, and cyclooxygenase -2 (Cox-2) expression thereby suppressed PGD2 release after intranasal curcumin treatment
- Cytokine response (Th2 and Th1 both) has been affected by intranasal curcumin.
- Activation (phosphorylation) of MAPkinases (p38, Erk and JNK) has been attenuated after intranasal curcumin treatment.
Asthma, a multifactorial, chronic inflammatory disease encompasses multiple complex pathways releasing number of mediators by activated mast cells, eosinophils and T lymphocytes, leading to its severity. Presently available medications are associated with certain limitations, and hence, it is imperative to search for anti-inflammatory drug preferably targeting signaling cascades involved in inflammation thereby suppressing inflammatory mediators without any side effect. Curcumin, an anti-inflammatory molecule with potent anti-asthmatic potential has been found to suppress asthmatic features by inhibiting airway inflammation and bronchoconstriction if administered through nasal route. The present study provides new insight towards anti-asthmatic potential of intranasal curcumin at lower doses (2.5 and 5.0 mg/kg) in Balb/c mice sensitized and challenged with ovalbumin (OVA) which is effective in inhibiting airway inflammation. These investigations suggest that intranasal curcumin (2.5 and 5.0 mg/kg) regulates airway inflammation and airway obstruction mainly by modulating cytokine levels (IL-4, 5, IFN-ƴ and TNF-α) and sPLA2 activity thereby inhibiting PGD2 release and COX-2 expression. Further, the suppression of p38 MAPK, ERK 42/44 and JNK54/56 activation elucidate the mechanism behind the inhibitory role of intranasal curcumin in asthma progression. Thus, curcumin could be better alternative for the development of nasal formulations and inhalers in near future.
Journal: International Immunopharmacology - Volume 31, February 2016, Pages 200-206